AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01089998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9596
Description: Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
Study NCT01089998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9596
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
Study NCT01089998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9596
Description: Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
Study NCT01089998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose (18F)-IBA
Description: Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
Study NCT01937598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients administered a single dose of placebo during a mixed meal challenge.
Study NCT01937598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal test
Description: Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
Study NCT01937598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
Study NCT01937598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Patients administered a single dose of Sitagliptin during a mixed meal challenge.
Study NCT03404284 — intervention group
Intervention type: BEHAVIORAL
Intervention: Family planning and infant immunization service integration
Description: The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
Study NCT01700270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib (TKI258)
Study NCT01700270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: perpetrator drug; 7 days of dosing
Study NCT01713270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic denervation
Description: Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
Study NCT01713270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drug
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
Study NCT01713270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
Study NCT01713270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct-Current Cardioversion
Description: After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
Study NCT02116257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol
Description: total 4g of Propacetamol added to patient's PCA regimen
Study NCT02116257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PCA regimen
Study NCT04173884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.
Study NCT04173884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constructive Feedback
Description: Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
Study NCT01763151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toric IOL
Description: implantation of an aspheric, toric, acrylic IOL during cataract surgery
Study NCT01763151 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL combined with opposite clear corneal incision (OCCI)
Description: aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
Study NCT02018198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FebriDx
Description: Point of Care Host Immune Response Test
Study NCT01665547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-carnitine
Description: 3gm l-carnitine from day 1 to day 12 of the menstrual cycle
Study NCT05406843 — intervention group
Intervention type: OTHER
Intervention: Preoperative cognitive functions of participants undergoing open heart surgery
Description: Surgery times and cross-clamping times of the participants who will undergo open heart surgery were recorded.
Study NCT05406843 — intervention group
Intervention type: OTHER
Intervention: Postoperative cognitive functions of particiants undergoing open heart surgery
Description: Changes in mini mental test scores were recorded in the postoperative period.
Study NCT02846350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision
Study NCT03654976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet
Description: Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
Study NCT03654976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet, for daily administration (1 tablet per day)
Study NCT01811784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask people not to drink raw sap
Study NCT01811784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask people not to drink sap or drink sap from skirt protected trees
Description: Behavioural
Study NCT01811784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Study NCT00110981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB
Description: Three times a week (TIW) for 12 weeks
Study NCT00110981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanerept
Description: 50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
Study NCT00110981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
Study NCT01572675 — intervention group
Intervention type: DRUG
Intervention: etorocoxib
Description: Administered as 30 mg or 60 mg oral film-coated tablets
Study NCT01572675 — intervention group
Intervention type: DRUG
Intervention: celecoxib
Description: Administered as 100 mg or 200 mg oral hard capsules
Study NCT03470038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection
Study NCT03470038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: Intramuscular injection
Study NCT00201669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
Study NCT04158921 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control:Diabetes mobile app
Description: The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. > 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
Study NCT02483624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-DIM
Description: DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
Study NCT02483624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01358760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppository
Study NCT01358760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.25% (3.25 mg) DHEA
Study NCT01358760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.5% (6.5 mg) DHEA
Study NCT02794077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
Study NCT00961753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized ibuprofen
Description: day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
Study NCT00961753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
Study NCT00598260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induction of labor
Description: study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
Study NCT00517153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
Study NCT04169490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Cream Base Emulsion Moisturizer
Description: Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
Study NCT04169490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FS2 Emulsion Moisturizer
Description: Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
Study NCT04169490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator Onion Skin Extract Gel (Mederma)
Description: Topical onion skin extract gel (Mederma) applied b.d. for 120 days
Study NCT04169490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator Silicone Gel (Kelo-Cote)
Description: Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
Study NCT04169490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Description: Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
Study NCT04444960 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
Study NCT01925352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-HGF
Description: 5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
Study NCT01637909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.
Description: All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
Study NCT01637909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment group 1(Dietary intervention)
Description: The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
Study NCT01637909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group 2(dietary and exercise intervention)
Description: The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
Study NCT02019823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational SMS-text
Study NCT02019823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive SMS-text
Study NCT02019823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Study NCT02019823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Study NCT01212978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer to Increase Physical Activity
Description: The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
Study NCT01212978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer to Increase Physical Activity
Description: The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
Study NCT04297501 — intervention group
Intervention type: DRUG
Intervention: Antiretroviral Therapy
Description: All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
Study NCT02975193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer task assessing cognition
Description: Participants will complete a short computer game to assess cognition.
Study NCT02975193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impulsive-Compulsive Disorders in Parkinson's Disease
Description: Standard clinical questionnaire
Study NCT02975193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation Surgery
Description: DBS surgery for the implantation of electrodes for the treatment of motor disorders.
Study NCT01519765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Misoprostol
Description: Buccal rather than Vaginal misoprostol for induction of labor
Study NCT01519765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: Vaginal rather than buccal misoprostol for induction of labor
Study NCT04819256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PACE-It mobile application
Description: Care co-ordination platform
Study NCT01806857 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nuedexta
Description: Nuedexta PO (by mouth) for 28 ± 3 days
Study NCT01806857 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Matching Placebo
Description: matching placebo PO (by mouth) for 28 ± 3 days
Study NCT03752008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play (AP)
Description: This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.